Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Connected diagnostics: linking digital rapid diagnostic tests and mobile health wallets to diagnose and treat brucellosis in Samburu, Kenya.

Smith S, Koech R, Nzorubara D, Otieno M, Wong L, Bhat G, van den Bogaart E, Thuranira M, Onchonga D, Rinke de Wit TF.

BMC Med Inform Decis Mak. 2019 Jul 22;19(1):139. doi: 10.1186/s12911-019-0854-4.

2.

Long-term virological outcomes, failure and acquired resistance in a large cohort of Ugandan children.

Huibers MHW, Kityo C, Boerma RS, Kaudha E, Sigaloff KCE, Balinda SN, Bertagnolio S, Nakanjako R, Mugyenyi P, Calis JCJ, Boele van Hensbroek M, Rinke de Wit TF.

J Antimicrob Chemother. 2019 Oct 1;74(10):3035-3043. doi: 10.1093/jac/dkz266.

PMID:
31289811
3.

Systematic review of the performance and clinical utility of point of care HIV-1 RNA testing for diagnosis and care.

Agutu CA, Ngetsa CJ, Price MA, Rinke de Wit TF, Omosa-Manyonyi G, Sanders EJ, Graham SM.

PLoS One. 2019 Jun 27;14(6):e0218369. doi: 10.1371/journal.pone.0218369. eCollection 2019.

4.

PrEP interest and HIV-1 incidence among MSM and transgender women in coastal Kenya.

Kimani M, van der Elst EM, Chiro O, Oduor C, Wahome E, Kazungu W, Shally M, Rinke de Wit TF, Graham SM, Operario D, Sanders EJ.

J Int AIDS Soc. 2019 Jun;22(6):e25323. doi: 10.1002/jia2.25323.

5.

Plasma Biomarkers of Human Immunodeficiency Virus-Related Systemic Inflammation and Immune Activation in Sub-Saharan Africa Before and During Suppressive Antiretroviral Therapy.

Kroeze S, Wit FW, Rossouw TM, Steel HC, Kityo CM, Siwale M, Akanmu S, Mandaliya K, de Jager M, Ondoa P, Reiss P, Rinke de Wit TF, Kootstra N, Hamers RL.

J Infect Dis. 2019 Aug 9;220(6):1029-1033. doi: 10.1093/infdis/jiz252.

6.

Reaching 90-90-90: outcomes of a 15-year multi-country HIV workplace programme in sub-Saharan Africa.

Boerma R, Schellekens O, Rinke de Wit TF, Wit FW, van der Borght S, Rijckborst H, Chukwumah P, Schilthuis H.

Antivir Ther. 2019 Apr 24. doi: 10.3851/IMP3311. [Epub ahead of print]

PMID:
31017125
7.

Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens.

Inzaule SC, Hamers RL, Doherty M, Shafer RW, Bertagnolio S, Rinke de Wit TF.

Lancet Infect Dis. 2019 Jul;19(7):e246-e252. doi: 10.1016/S1473-3099(18)30710-2. Epub 2019 Mar 19. Review.

PMID:
30902440
8.

Using mobile transport vouchers to improve access to skilled delivery.

Ommeh M, Fenenga CJ, Hesp CJ, Nzorubara D, Rinke de Wit TF.

Rural Remote Health. 2019 Feb;19(1):4577. doi: 10.22605/RRH4577. Epub 2019 Feb 9.

9.

Does Tenofovir-containing First-line Antiretroviral Therapy Mitigate the Impact of Pretreatment Non-nucleoside Reverse Transcriptase Inhibitor Drug Resistance?

Inzaule SC, Rinke de Wit TF, Hamers RL; Pan-African Studies to Evaluate Resistance .

Clin Infect Dis. 2019 May 30;68(12):2158-2160. doi: 10.1093/cid/ciy1070. No abstract available.

PMID:
30561519
10.

Previous antiretroviral drug use compromises standard first-line HIV therapy and is mediated through drug-resistance.

Inzaule SC, Kityo CM, Siwale M, Akanmu AS, Wellington M, de Jager M, Ive P, Mandaliya K, Stevens W, Boender TS, Ondoa P, Sigaloff KCE, Naniche D, Rinke de Wit TF, Hamers RL.

Sci Rep. 2018 Oct 25;8(1):15751. doi: 10.1038/s41598-018-33538-0.

11.

Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.

Inzaule SC, Hamers RL, Noguera-Julian M, Casadellà M, Parera M, Kityo C, Steegen K, Naniche D, Clotet B, Rinke de Wit TF, Paredes R; PanAfrican Studies to Evaluate Resistance.

Lancet HIV. 2018 Nov;5(11):e638-e646. doi: 10.1016/S2352-3018(18)30177-2. Epub 2018 Sep 30.

PMID:
30282603
12.

Association between HIV-1 subtype and drug resistance in Nigerian infants.

Chaplin B, Akanmu AS, Inzaule SC, Samuels JO, Okonkwo P, Ilesanmi O, Adewole IFA, Asadu C, Khamofu H, Mpazanje R, Ndembi N, Odafe S, Sigaloff KCE, Ngige EN, Abatta EO, Akinbiyi G, Dakum P, Rinke de Wit TF, Kanki P.

J Antimicrob Chemother. 2019 Jan 1;74(1):172-176. doi: 10.1093/jac/dky380.

PMID:
30260417
13.

HIV drug resistance in low-income and middle-income countries.

Hamers RL, Rinke de Wit TF, Holmes CB.

Lancet HIV. 2018 Oct;5(10):e588-e596. doi: 10.1016/S2352-3018(18)30173-5. Epub 2018 Sep 4. Review.

PMID:
30193863
14.

Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa.

Kroeze S, Ondoa P, Kityo CM, Siwale M, Akanmu S, Wellington M, de Jager M, Ive P, Mandaliya K, Stevens W, Boender TS, de Pundert ME, Sigaloff KCE, Reiss P, Wit FWNM, Rinke de Wit TF, Hamers RL.

AIDS. 2018 May 15;32(8):1043-1051. doi: 10.1097/QAD.0000000000001801.

PMID:
29547445
15.

HIV Drug Resistance.

Inzaule SC, Rinke de Wit TF, Hamers RL.

N Engl J Med. 2018 Mar 1;378(9):873-4. doi: 10.1056/NEJMc1716089. No abstract available.

PMID:
29504387
16.

Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa.

Inzaule SC, Hamers RL, Noguera-Julian M, Casadellà M, Parera M, Rinke de Wit TF, Paredes R.

J Antimicrob Chemother. 2018 May 1;73(5):1167-1172. doi: 10.1093/jac/dky005.

PMID:
29462322
17.

When prevention of mother-to-child HIV transmission fails: preventing pretreatment drug resistance in African children.

Inzaule SC, Hamers RL, Calis J, Boerma R, Sigaloff K, Zeh C, Mugyenyi P, Akanmu S, Rinke de Wit TF.

AIDS. 2018 Jan 14;32(2):143-147. doi: 10.1097/QAD.0000000000001696. No abstract available.

PMID:
29135578
18.

High Prevalence of HIV Drug Resistance Among Newly Diagnosed Infants Aged <18 Months: Results From a Nationwide Surveillance in Nigeria.

Inzaule SC, Osi SJ, Akinbiyi G, Emeka A, Khamofu H, Mpazanje R, Ilesanmi O, Ndembi N, Odafe S, Sigaloff KCE, Rinke de Wit TF, Akanmu S.

J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):e1-e7. doi: 10.1097/QAI.0000000000001553.

PMID:
28961680
19.

Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: adolescents at high risk of failure.

Boerma RS, Bunupuradah T, Dow D, Fokam J, Kariminia A, Lehman D, Kityo C, Musiime V, Palumbo P, Schoffelen A, Sophan S, Zanoni B, Rinke de Wit TF, Calis JCJ, Sigaloff KCE; Paediatric Second-line Study Group.

J Int AIDS Soc. 2017 Sep 15;20(1):21930. doi: 10.7448/IAS.20.1.21930.

20.

Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children.

Kityo C, Boerma RS, Sigaloff KCE, Kaudha E, Calis JCJ, Musiime V, Balinda S, Nakanjako R, Boender TS, Mugyenyi PN, Rinke de Wit TF.

J Antimicrob Chemother. 2017 Sep 1;72(9):2587-2595. doi: 10.1093/jac/dkx188.

21.

Emergence of untreatable, multidrug-resistant HIV-1 in patients failing second-line therapy in Kenya.

Inzaule SC, Hamers RL, Mukui I, Were K, Owiti P, Kwaro D, Rinke de Wit TF, Zeh C.

AIDS. 2017 Jun 19;31(10):1495-1498. doi: 10.1097/QAD.0000000000001500.

PMID:
28398959
22.

Adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts.

Bijker R, Jiamsakul A, Kityo C, Kiertiburanakul S, Siwale M, Phanuphak P, Akanmu S, Chaiwarith R, Wit FW, Sim BL, Boender TS, Ditangco R, Rinke De Wit TF, Sohn AH, Hamers RL.

J Int AIDS Soc. 2017 Mar 3;20(1):21218. doi: 10.7448/IAS.20.1.21218.

23.

The Evolving Landscape of HIV Drug Resistance Diagnostics for Expanding Testing in Resource-Limited Settings.

Inzaule SC, Hamers RL, Paredes R, Yang C, Schuurman R, Rinke de Wit TF.

AIDS Rev. 2017 Oct-Dec;19(4):219-230. Review.

PMID:
28182618
24.

Correction: Long-Term Antiretroviral Treatment Adherence in HIV-Infected Adolescents and Adults in Uganda: A Qualitative Study.

Inzaule SC, Hamers RL, Kityo C, Rinke de Wit TF, Roura M.

PLoS One. 2017 Feb 8;12(2):e0172077. doi: 10.1371/journal.pone.0172077. eCollection 2017.

25.

Uptake and Acceptability of Oral HIV Self-Testing among Community Pharmacy Clients in Kenya: A Feasibility Study.

Mugo PM, Micheni M, Shangala J, Hussein MH, Graham SM, Rinke de Wit TF, Sanders EJ.

PLoS One. 2017 Jan 26;12(1):e0170868. doi: 10.1371/journal.pone.0170868. eCollection 2017.

26.

Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis.

Boerma RS, Sigaloff KC, Akanmu AS, Inzaule S, Boele van Hensbroek M, Rinke de Wit TF, Calis JC.

J Antimicrob Chemother. 2017 Feb;72(2):365-371. doi: 10.1093/jac/dkw463. Epub 2016 Dec 20. Review.

PMID:
27999070
27.

Long-Term Antiretroviral Treatment Adherence in HIV-Infected Adolescents and Adults in Uganda: A Qualitative Study.

Inzaule SC, Hamers RL, Kityo C, Rinke de Wit TF, Roura M.

PLoS One. 2016 Nov 29;11(11):e0167492. doi: 10.1371/journal.pone.0167492. eCollection 2016. Erratum in: PLoS One. 2017 Feb 8;12 (2):e0172077.

28.

High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children.

Boerma RS, Boender TS, Sigaloff KC, Rinke de Wit TF, van Hensbroek MB, Ndembi N, Adeyemo T, Temiye EO, Osibogun A, Ondoa P, Calis JC, Akanmu AS.

J Int AIDS Soc. 2016 Nov 10;19(1):21140. doi: 10.7448/IAS.19.1.21140. eCollection 2016.

29.

Suboptimal Viral Suppression Rates Among HIV-Infected Children in Low- and Middle-Income Countries: A Meta-analysis.

Boerma RS, Boender TS, Bussink AP, Calis JC, Bertagnolio S, Rinke de Wit TF, Boele van Hensbroek M, Sigaloff KC.

Clin Infect Dis. 2016 Dec 15;63(12):1645-1654. Epub 2016 Sep 22.

PMID:
27660236
30.

Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance.

Boerma RS, Kityo C, Boender TS, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde L, Mugyenyi PN, Boele van Hensbroek M, Rinke de Wit TF, Sigaloff KCE, Calis JCJ.

J Trop Pediatr. 2017 Apr 1;63(2):135-143. doi: 10.1093/tropej/fmw062. Erratum in: J Trop Pediatr. 2016 Oct 15;:null.

PMID:
27634175
31.

Assessing the Impact of Community Engagement Interventions on Health Worker Motivation and Experiences with Clients in Primary Health Facilities in Ghana: A Randomized Cluster Trial.

Alhassan RK, Nketiah-Amponsah E, Spieker N, Arhinful DK, Rinke de Wit TF.

PLoS One. 2016 Jul 20;11(7):e0158541. doi: 10.1371/journal.pone.0158541. eCollection 2016.

32.

Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.

Boender TS, Hamers RL, Ondoa P, Wellington M, Chimbetete C, Siwale M, Labib Maksimos EE, Balinda SN, Kityo CM, Adeyemo TA, Akanmu AS, Mandaliya K, Botes ME, Stevens W, Rinke de Wit TF, Sigaloff KC.

J Infect Dis. 2016 Sep 15;214(6):873-83. doi: 10.1093/infdis/jiw219. Epub 2016 Jul 11.

PMID:
27402780
33.

Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.

Boender TS, Kityo CM, Boerma RS, Hamers RL, Ondoa P, Wellington M, Siwale M, Nankya I, Kaudha E, Akanmu AS, Botes ME, Steegen K, Calis JC, Rinke de Wit TF, Sigaloff KC.

J Antimicrob Chemother. 2016 Oct;71(10):2918-27. doi: 10.1093/jac/dkw218. Epub 2016 Jun 23.

PMID:
27342546
34.

Perspectives of frontline health workers on Ghana's National Health Insurance Scheme before and after community engagement interventions.

Alhassan RK, Nketiah-Amponsah E, Spieker N, Arhinful DK, Rinke de Wit TF.

BMC Health Serv Res. 2016 May 28;16:192. doi: 10.1186/s12913-016-1438-y.

35.

Effect of Text Message, Phone Call, and In-Person Appointment Reminders on Uptake of Repeat HIV Testing among Outpatients Screened for Acute HIV Infection in Kenya: A Randomized Controlled Trial.

Mugo PM, Wahome EW, Gichuru EN, Mwashigadi GM, Thiong'o AN, Prins HA, Rinke de Wit TF, Graham SM, Sanders EJ.

PLoS One. 2016 Apr 14;11(4):e0153612. doi: 10.1371/journal.pone.0153612. eCollection 2016.

36.

Prevalence and dynamics of the K65R drug resistance mutation in HIV-1-infected infants exposed to maternal therapy with lamivudine, zidovudine and either nevirapine or nelfinavir in breast milk.

Inzaule SC, Weidle PJ, Yang C, Ndiege K, Hamers RL, Rinke de Wit TF, Thomas T, Zeh C.

J Antimicrob Chemother. 2016 Jun;71(6):1619-26. doi: 10.1093/jac/dkw039. Epub 2016 Mar 6.

PMID:
26953333
37.

Clinical Evaluation of an Affordable Qualitative Viral Failure Assay for HIV Using Dried Blood Spots in Uganda.

Balinda SN, Ondoa P, Obuku EA, Kliphuis A, Egau I, Bronze M, Kasambula L, Schuurman R, Spieker N, Rinke de Wit TF, Kityo C; ART–A consortium.

PLoS One. 2016 Jan 29;11(1):e0145110. doi: 10.1371/journal.pone.0145110. eCollection 2016.

38.

HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda.

Kityo C, Sigaloff KC, Sonia Boender T, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde-Katumba L, Calis JC, Rinke de Wit TF, Mugyenyi PN.

AIDS Res Hum Retroviruses. 2016 Jul;32(7):628-35. doi: 10.1089/AID.2015.0215. Epub 2016 Feb 11.

39.

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.

Rhee SY, Jordan MR, Raizes E, Chua A, Parkin N, Kantor R, Van Zyl GU, Mukui I, Hosseinipour MC, Frenkel LM, Ndembi N, Hamers RL, Rinke de Wit TF, Wallis CL, Gupta RK, Fokam J, Zeh C, Schapiro JM, Carmona S, Katzenstein D, Tang M, Aghokeng AF, De Oliveira T, Wensing AM, Gallant JE, Wainberg MA, Richman DD, Fitzgibbon JE, Schito M, Bertagnolio S, Yang C, Shafer RW.

PLoS One. 2015 Dec 30;10(12):e0145772. doi: 10.1371/journal.pone.0145772. eCollection 2015.

40.

Efficiency of private and public primary health facilities accredited by the National Health Insurance Authority in Ghana.

Alhassan RK, Nketiah-Amponsah E, Akazili J, Spieker N, Arhinful DK, Rinke de Wit TF.

Cost Eff Resour Alloc. 2015 Dec 26;13:23. doi: 10.1186/s12962-015-0050-z. eCollection 2015.

41.

Sequencing paediatric antiretroviral therapy in the context of a public health approach.

Boerma RS, Boender TS, van Hensbroek MB, Rinke de Wit TF, Sigaloff KC.

J Int AIDS Soc. 2015 Dec 2;18(Suppl 6):20265. doi: 10.7448/IAS.18.7.20265. eCollection 2015. Review.

42.

Effect of Community Engagement Interventions on Patient Safety and Risk Reduction Efforts in Primary Health Facilities: Evidence from Ghana.

Alhassan RK, Nketiah-Amponsah E, Spieker N, Arhinful DK, Ogink A, van Ostenberg P, Rinke de Wit TF.

PLoS One. 2015 Nov 30;10(11):e0142389. doi: 10.1371/journal.pone.0142389. eCollection 2015.

43.

Assessing the costs of mobile voluntary counseling and testing at the work place versus facility based voluntary counseling and testing in Namibia.

de Beer I, Chani K, Feeley FG, Rinke de Wit TF, Sweeney-Bindels E, Mulongeni P.

Rural Remote Health. 2015 Oct-Dec;15(4):3357. Epub 2015 Nov 13.

44.

Comparison of Perceived and Technical Healthcare Quality in Primary Health Facilities: Implications for a Sustainable National Health Insurance Scheme in Ghana.

Alhassan RK, Duku SO, Janssens W, Nketiah-Amponsah E, Spieker N, van Ostenberg P, Arhinful DK, Pradhan M, Rinke de Wit TF.

PLoS One. 2015 Oct 14;10(10):e0140109. doi: 10.1371/journal.pone.0140109. eCollection 2015.

45.

Stringent HIV Viral Load Threshold for Virological Failure Using Dried Blood Spots: Is the Perfect the Enemy of the Good?

Inzaule SC, Hamers RL, Zeh CE, Rinke de Wit TF.

J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):e30-3. doi: 10.1097/QAI.0000000000000828. No abstract available.

PMID:
26334744
46.

Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.

Boender TS, Hoenderboom BM, Sigaloff KC, Hamers RL, Wellington M, Shamu T, Siwale M, Labib Maksimos EE, Nankya I, Kityo CM, Adeyemo TA, Akanmu AS, Mandaliya K, Botes ME, Ondoa P, Rinke de Wit TF.

Clin Infect Dis. 2015 Dec 1;61(11):1749-58. doi: 10.1093/cid/civ656. Epub 2015 Aug 3.

PMID:
26240203
47.

Prevalence and Knowledge Assessment of HIV and Non-Communicable Disease Risk Factors among Formal Sector Employees in Namibia.

Guariguata L, de Beer I, Hough R, Mulongeni P, Feeley FG, Rinke de Wit TF.

PLoS One. 2015 Jul 13;10(7):e0131737. doi: 10.1371/journal.pone.0131737. eCollection 2015.

48.

Long-term Virological Outcomes of First-Line Antiretroviral Therapy for HIV-1 in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.

Boender TS, Sigaloff KC, McMahon JH, Kiertiburanakul S, Jordan MR, Barcarolo J, Ford N, Rinke de Wit TF, Bertagnolio S.

Clin Infect Dis. 2015 Nov 1;61(9):1453-61. doi: 10.1093/cid/civ556. Epub 2015 Jul 8. Review.

49.

Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.

Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, Rinke de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Ng KP, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HM, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW.

PLoS Med. 2015 Apr 7;12(4):e1001810. doi: 10.1371/journal.pmed.1001810. eCollection 2015 Apr. Erratum in: PLoS Med. 2015 Jun;12(6):e1001845.

50.

Research in action: from AIDS to global health to impact. A symposium in recognition of the scientific contributions of Professor Joep Lange.

Boender TS, Barré-Sinoussi F, Cooper D, Goosby E, Hankins C, Heidenrijk M, de Jong M, Kazatchkine M, Laoye F, Merson M, Reiss P, Rinke de Wit TF, Rogo K, Schellekens O, Schultsz C, Sigaloff KC, Simon J, Zewdie D.

Antivir Ther. 2015;20(1):101-8. doi: 10.3851/IMP2946. Epub 2015 Feb 18. No abstract available.

PMID:
25691450

Supplemental Content

Loading ...
Support Center